R&D Projects

ANXARECU

Validation of annexin 2 as a predictor of recurrence in endometrial cancer. Design of new therapeutic strategies

The aim of the project is to develop a predictive method for the recurrence of endometrial cancer, based on the expression of annexin 2 (ANXA2), which allows both the detection of patients with the possibility of recurrence at the time of diagnosis and clinical follow-up, as well as the validation of therapies aimed at these patient populations.

6k+

of endometrial cancer cases per year in Spain

detailGrey

The aim of the project is to improve the detection, diagnosis, and treatment of endometrial cancer.

In order to successfully achieve the project’s aim, a consortium has been formed with Formune Vaccines SL, the Institut de Recerca Biomédica de Lleida, the Fundació Privada Dr Pifarré, and the Fundació Hospital Universitai Vall d’Hebrón – Institut de Recerca.

To achieve the objectives

RTC-2014-3110-1 2014-2016

The project is co-funded by the Ministry of Economy and Competitiveness, within the call Challenges-Collaboration of the State Programme for Research, Development, and Innovation Oriented to the Challenges of Society, within the framework of the State Plan for Scientific and Technical Research and Innovation 2013-2016.

Financial blockers

Related projects

ADELIS

ADELIS

Pharmacogenomic evaluation for the treatment of breast cancer with aromatase inhibitors

Read more
GLIBIOLIQUID

GLIBIOLIQUID

Diagnostic kit from blood sample blood sample in patients with brain tumor

Read more
PREDIAPT

PREDIAPT

Predictive system for assessing response to platinum-derived treatment in lung cancer

Read more
ZITOMAB

ZITOMAB

Second-generation antitumor immunotherapies: antibodies and toxin-conjugated nanobodies using Inteins-ZIP

Read more